Flotations versus blank cheques
Neither route to the stock market covered itself in glory in the recent bull market. But how do returns really stack up?
The ink dries on the blank cheque craze
As Apexigen throws in the towel six months after listing, can any bright spots be found in the stats on Spacs?
T-cell receptor behemoths consolidate? Not quite
Adaptimmune merges with TCR2, but the move is effectively an equity raise with benefits.
Conditions are ripe for reverse mergers
Redx makes the most of Jounce’s demise, but is the poor reputation of reverse mergers warranted?
US deal watchdog's bark could be worse than its bite
Chills in the biopharma M&A market are frequently blamed on the FTC. But is the agency really stopping deals from happening?
